AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year—was ...

Amylyx Pharmaceuticals said on Wednesday it will stop development of its experimental drug for a rare brain disorder after it ...

Learn how the Parker Solar Probe's passage through the Sun's outer atmosphere has shed light on the process that creates ...

Amylyx Pharmaceuticals has discontinued a clinical programme evaluating a neuronal cell death inhibitor as a result of ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...